Navigation Links
Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone

-- Additional Findings Reported Safety & Tolerability Profile in Subjects with Type 2 Diabetes and Healthy Subjects --

CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Phase III data presented this week at the annual meeting of the American Diabetes Association demonstrated that saxagliptin, an inhibitor of dipeptidyl-peptidase-4 (DPP-4) in development by Bristol-Myers Squibb Company and AstraZeneca , in combination with metformin, exhibited a statistically significant improvement in glycemic control in subjects with Type 2 diabetes compared to metformin alone through 24 weeks of treatment. This was the first time that Phase III data for saxagliptin have been presented in a scientific setting.

A group of 743 subjects (ages 18-77) with Type 2 diabetes whose hemoglobin A1C level was within the range of greater than or equal to 7 percent or less than or equal to 10 percent and on a stable metformin dose alone (1500 to 2550 mg/day) were randomized 1:1:1:1 to add-on saxagliptin 2.5 mg, 5 mg, 10 mg, or placebo once daily. The primary endpoint of the study was the change from baseline in hemoglobin A1C levels. After 24 weeks, the subjects receiving saxagliptin+metformin demonstrated statistically significant decreases in hemoglobin A1C levels compared to placebo+metformin: -0.73 percent, -0.83 percent, and -0.72 percent at the 2.5 mg, 5 mg and 10 mg doses, respectively (p-value at all dosage levels less than 0.0001 vs. placebo+metformin).

Saxagliptin+metformin also statistically significantly reduced fasting plasma glucose (secondary endpoint) as compared to placebo+metformin: -16 mg/dL, -23 mg/dL, and -22 mg/dL for saxagliptin 2.5 mg, 5 mg and 10 mg, respectively (p-value at all dosage levels less than 0.0001 vs. placebo+metformin). The percentage of subjects with hemoglobin A1C less than 7 percent at Week 24 (secondary endpoint) was 17 percent for placebo+metformin and 37 percent, 44 percent and 44
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
5. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
6. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
8. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
Post Your Comments:
(Date:5/4/2015)... Md. , May 4, 2015   Synthetic ... pathogen-specific therapeutics focused on protecting the microbiome, as well ... has been appointed Chief Financial Officer, Treasurer and ... Evan Ballantyne who will be leaving the Company ... Shallcross brings to Synthetic Biologics operational, financial and international ...
(Date:5/4/2015)... and COLUMBIA, Maryland , May ... SHP, NASDAQ: SHPG ) and the Foundation Fighting ... research for a novel treatment for autosomal dominant retinitis ... occurs in late childhood or adolescence and is followed ... no currently approved treatment options for adRP. ...
(Date:5/4/2015)... , le 4 mai 2015  Lors du ... /Allemagne (hall 5, stand 5510), North Star Imaging ... système à rayons X spécialement conçu pour la ... sur les rayons X, la CXMM 50, a ... système de métrologie destiné à offrir à l,utilisateur ...
Breaking Medicine Technology:Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 2Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 3Shire and Foundation Fighting Blindness Announce New Research Agreement 2Shire and Foundation Fighting Blindness Announce New Research Agreement 3NSI sera présente lors du salon Control 2015, du 5 au 8 mai à Stuttgart, en Allemagne : axer la GMAO vers une nouvelle dimension 2
... Quest Diagnostics Incorporated (NYSE: DGX ), the ... announced the availability in Europe of the Simplexa C. ... The new CE marked in vitro diagnostic (IVD) ... traditional extraction step and allowing for processing of up to ...
... 2011 Bacterin International Holdings, Inc. ("Bacterin") ... developer of revolutionary bone graft material and antimicrobial coatings ... distribution of the Company,s third human acellular biological scaffold, ... hMatrix® is an acellular matrix processed from donated human ...
Cached Medicine Technology:Quest Diagnostics Launches Simplexa™ C. Difficile Universal Direct Test in Europe 2Quest Diagnostics Launches Simplexa™ C. Difficile Universal Direct Test in Europe 3Quest Diagnostics Launches Simplexa™ C. Difficile Universal Direct Test in Europe 4Bacterin International Holdings Launches Third Biologic Scaffold 2Bacterin International Holdings Launches Third Biologic Scaffold 3
(Date:5/4/2015)... 04, 2015 World T.E.A.M. Sports’ best-attended ... ride in the last decade arrived in this historic ... in two days from the Pentagon in Arlington, Virginia. ... registered disabled and able-bodied participants work together to successfully ... and honors the commitment and sacrifices by military veterans ...
(Date:5/4/2015)... 04, 2015 “ Food Cost Calculator ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... owners to manage and efficiently calculate food costs. , The ... In fact, the industry has an estimated 1.8 trillion dollar ...
(Date:5/4/2015)... 04, 2015 Peacock Alley knows ... He said, “My mother was the most beautiful woman I ... in lovely, feminine prints and textures to remind ... further than the Eloise Robe to get you there. The ... cap sleeve and tapered waist. It is available in small/medium ...
(Date:5/4/2015)... Sara Soulati, CEO of Global Cardio ... Los Angeles associated with the field of Enhanced External ... Sara Soulati Health For Life Program (SSHFLP). , The ... modification and disease prevention program. A provisional patent ... Patents and Trademarks Office and is now under review ...
(Date:5/3/2015)... May 03, 2015 Women’s Excellence ... Facebook page. , Their Facebook page consists ... services the Practice has, it’s multiple locations, Providers and ... Excellence has a very strong social media presence, with ... You Tube. , Women’s Excellence is the most ...
Breaking Medicine News(10 mins):Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... TV/Channel 7 and The,Detroit Department of Health and Wellness ... "boost" at the 31st annual "HEALTHY LIVING,FOR KIDS" program. ... 24,2008 from 10 a.m. to 5 p.m. at the ... inception in 1977, "Healthy Living for Kids",has provided free ...
... -- Tianyin,Pharmaceutical, Co., Inc. (OTC Bulletin Board: TYNP, ... medicine ("TCM") based in,Chengdu, China, today announced that ... OTC BB: TYNPE due to the electronic eligibility,system ... and the Company expects the,stock symbol to trade ...
... Fourteen physicians who have been,part of Commonwealth Medical ... and service they provide to their patients by joining ... and we are delighted they,have decided to join our ... officer. "We look forward to working with,them to support ...
... Aug. 20 Governor Edward,G. Rendell today said ... and a broken healthcare system, underscoring the need,to ... more,affordable for working adults., Nearly 900 guests ... & Industry Day Luncheon at Ag Progress Days, ...
... traitors, good cells gone bad. They evade the body,s defense ... , But researchers at the University of North Carolina at ... way to blow their cover. , Moo J. Cho, Ph.D., ... system that would embed bacterial elements in a cancer tumor ...
... found that infusions of a particular bone marrow stem ... in a mouse model. In their report published ... from the MGH Center for Engineering in Medicine report ... immune system activities, allowed the regeneration of the gastrointestinal ...
Cached Medicine News:Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction 2Health News:Commonwealth Medical Group Physicians to Join Aurora Health Care 2Health News:Pennsylvania Governor Rendell Highlights Renewable Energy, Health Care Reform at Ag Progress Days 2Health News:UNC researcher aims to 'unmask' cancer cells to trigger body's immune system 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 3
... bed side and near patient testing is ... growth has posed unique problems for hospitals ... quality responsibility to decentralized areas focused on ... the problem is the reality of controlling ...
... The GenoSensor System includes genomic ... software, and reagents. By utilizing ... (CGH) technology for multi-target assessment, ... analyze multiple genomic targets in ...
... The CELL-DYN 3700 combines optical light ... Polarized Scatter Separation (MAPSS) to fully ... to improve performance and productivity in ... the revolutionary concept of complementary technologies ...
... Data Networking is hospital bedside glucose ... networking. In seconds, point of care ... from nursing stations throughout the hospital ... available to laboratory staff and the ...
Medicine Products: